3-benzyloxy-2-ethyl-1-methylpyrid-4-one | 123742-56-3

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 3-benzyloxy-2-ethyl-1-methylpyrid-4-one
• 英文别名: 3-benzyloxy-2-ethyl-1-methyl-4(1H)-pyridinone；3-Benzyloxy-2-ethyl-1-methylpyrid4-one；2-ethyl-1-methyl-3-phenylmethoxypyridin-4-one
• CAS: 123742-56-3
• 化学式: C₁₅H₁₇NO₂
• 分子量: 243.305
• InChiKey: RURWAHJRBWMFQL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  18
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.27
• 拓扑面积：
  29.5
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  3-benzyloxy-2-ethyl-1-methylpyrid-4-one 在 palladium on activated charcoal 盐酸 、 氢气 作用下， 以 甲醇 为溶剂， 生成 1-甲基-2-乙基-3-羟基吡啶-4-酮
  参考文献：
  名称：

  Burgess, John; Fawcett, John; Patel, Marttand S., Journal of Chemical Research, Miniprint, 1993, # 2, p. 214 - 246

  摘要：

  DOI：
• 作为产物：
  描述：

  乙基麦芽酚 在 sodium hydroxide 作用下， 以 甲醇 、 乙醇 、 水 为溶剂， 反应 24.0h， 生成 3-benzyloxy-2-ethyl-1-methylpyrid-4-one
  参考文献：
  名称：

  N-取代的2-烷基-3-羟基-4（1H）-吡啶酮的合成，理化性质和生物学评估：具有临床潜力的口服活性铁螯合剂。

  摘要：

  描述了一系列包含螯合部分3-羟基-4（1H）-吡啶酮的新型双齿配体的合成。已经确定了配体的pKa值及其铁（III）配合物的稳定性常数。给出了一种配体和一种铁（III）配合物的晶体结构。报告了配体的分布系数，并且与配体从肝细胞中去除铁的能力有关。描述了3-羟基-4（1H）-吡啶酮对细胞氧化损伤的影响。与目前的铁螯合剂去铁胺-B相比，本研究中描述的许多双齿配体在铁超载小鼠中具有口服活性。

  DOI：

  10.1021/jm00069a002

文献信息

• Esterified hydroxy dihydropyridinones for treating diseases associated
  申请人：Ciba-Geigy Corporation

  公开号：US04908371A1

  公开（公告）日：1990-03-13

  3-Substituted 4(1H)-pyridone compounds of formula ##STR1## wherein R.sub.1 is an unsubstituted or substituted hydrocarbon radical, X is a bond or a group of formula --O-- or --N(R.sub.3)--, wherein R.sub.3 is hydrogen or an unsubstituted or substituted hydrocarbon radical, and R.sub.2 is an unsubstituted or substituted hydrocarbon radical, or wherein R.sub.2 and R.sub.3, when taken together, are an unsubstituted or substituted divalent hydrocarbon radical, and wherein the other ring carbon atoms of the 4(1H)-pyridinone ring, independently of one another, are unsubstituted or substituted by an unsubstituted or substituted hydrocarbon radical or by etherified or esterified hydroxy, and salts of compounds of formula I with salt-forming properties, form chelate-type metal complexes, especially with trivalent metal ions, and can be used, for example, as pharmacologically active compounds.

  3-取代的4(1H)-吡啶酮化合物的化学式为##STR1##其中R.sub.1是未取代或取代的碳氢基团，X是一个键或化学式--O--或--N(R.sub.3)--的基团，其中R.sub.3是氢或未取代或取代的碳氢基团，而R.sub.2是未取代或取代的碳氢基团，或者R.sub.2和R.sub.3一起时，它们是未取代或取代的二价碳氢基团，4(1H)-吡啶酮环的其他环碳原子，独立地，未取代或被未取代或取代的碳氢基团或醚化或酯化的羟基取代，以及具有成盐性质的化合物的盐，形成螯合型金属络合物，特别是与三价金属离子，例如可用作药理活性化合物。
• Inhibitor development for 4-hydroxyphenylpyruvate dioxygenase, employing tyrosinemia 1 as a model for human diseases mediated by 2-oxoacid utilizing dioxygenases
  申请人：Hanauske-Abel M. Hartmut

  公开号：US20050288187A1

  公开（公告）日：2005-12-29

  The present invention is directed to a method of inhibiting 4-hydroxyphenylpyruvate dioxygenase in a living system by administering to the living system an effective amount of a compound of formulas I or II or III or derivatives thereof as follows: R 1 , R 2 , R 3 , and R 4 each individually represent a hydrogen, an alkyl, alkenyl, or alkoxy group containing 1 to about 8 carbon atoms, an aryl, aralkyl, or cycloalkyl group containing about 5 to 12 carbon atoms, or a carboalkoxy or carbamyl group containing up to 8 carbon atoms, or a peptide or peptidomimetic moiety containing 10 to about 30 carbon atoms under conditions effective to inhibit 4-hydroxyphenylpyruvate dioxygenase in the living system. These compounds are also useful in carrying out a method of treating a patient and a method of regulating plant growth.

  本发明涉及通过向生物体内投与式I或II或III或其衍生物的有效量来抑制生物体内4-羟基苯丙酮酸双氧酶的方法，其中：R1，R2，R3和R4分别表示氢，含1至约8个碳原子的烷基，烯基或烷氧基，含约5至12个碳原子的芳基，芳基烷基或环烷基，含多达8个碳原子的羧基烷氧基或氨基甲酰基，或含有10至约30个碳原子的肽或类肽基团，在有效条件下抑制生物体内的4-羟基苯丙酮酸双氧酶。这些化合物还可用于进行治疗患者的方法和调节植物生长的方法。
• Method for the treatment of fibroproliferative disorders by application
  申请人：Cornell Research Foundation, Inc.

  公开号：US05789426A1

  公开（公告）日：1998-08-04

  The present invention relates to a method of treating a patient with a fibrotic or fibroproliferative disorder and a method of suppressing formation of collagen and collagen-like substances or biosynthesis of procollagen in living systems by administering to a patient or living system, respectively, an effective amount of a compound of Formulae (I) or (II) and derivatives thereof: ##STR1## R.sub.1, R.sub.2, R.sub.3, and R.sub.4 each individually represent a hydrogen, an alkyl, alkenyl, or alkoxy group containing 1 to about 8 carbon atoms, an aryl, aralkyl, or cycloalkyl group containing about 5 to 12 carbon atoms, or a carboalkoxy or carbamyl group containing up to 8 carbon atoms, or a peptide or peptidomimetic moiety containing 10 to about 30 carbon atoms.

  本发明涉及一种治疗纤维化或纤维增生性疾病的患者的方法，以及通过向患者或生物系统分别投与式（I）或（II）化合物及其衍生物的有效剂量，来抑制胶原和类胶原物质的形成或前胶原在生物系统中的生物合成的方法： ##STR1## R.sub.1，R.sub.2，R.sub.3和R.sub.4分别表示氢，含有1到约8个碳原子的烷基，烯基或烷氧基，含有约5到12个碳原子的芳基，芳基烷基或环烷基，或含有多达8个碳原子的羧基烷氧基或氨基甲酰基，或含有10到约30个碳原子的肽或肽类似物基团。
• Method for the treatment of conditions mediated by collagen formation
  申请人：Cornell Research Foundation, Inc.

  公开号：US06046219A1

  公开（公告）日：2000-04-04

  The present invention relates to a method of treating conditions mediated by collagen formation together with cell proliferation by administering to a patient or living system an effective amount of a compound of Formulae (I) or (II) and derivatives thereof: ##STR1## R.sub.1, R.sub.2, R.sub.3, and R.sub.4 each individually represent a hydrogen, an alkyl, alkenyl, or alkoxy group containing 1 to about 8 carbon atoms, an aryl, aralkyl, or cycloalkyl group containing about 5 to 12 carbon atoms, or a carboalkoxy or carbamyl group containing up to 8 carbon atoms, or a peptide or peptidomimetic moiety containing 10 to about 30 carbon atoms.

  本发明涉及一种通过向患者或生物系统中给予式（I）或（II）化合物及其衍生物的有效量来治疗由胶原形成和细胞增殖介导的疾病的方法：##STR1##其中，R1、R2、R3和R4各自表示氢、含1至约8个碳原子的烷基、烯基或烷氧基、含约5至12个碳原子的芳基、芳基烷基或环烷基、含多达8个碳原子的羧基烷氧基或氨基甲酰基，或含有10至约30个碳原子的肽或肽类似物基团。
• Method of inhibiting viral replication in eukaryotic cells and of
  申请人：Cornell Research Foundation, Inc.

  公开号：US05849587A1

  公开（公告）日：1998-12-15

  The present invention is directed to methods which employ inhibition of the post-translational hypusine formation in the intracelluar protein eIF-5A, for the purpose of suppressing infections by viruses that parasitize eIF-5A so as to promote their own replication. Intentional inhibition of the post-translational formation of hypusine in infected host cells with compounds generically termed `hypusine inhibitors` not only selectively suppresses the production of viral proteins and of infectious viral particles, but also causes, particularly after hypusine inhibitor withdrawal, apoptosis in such virally-infected cells. Each of these methods, respectively, involves administering, to eukaryotic cells, tissues, or individuals, an agent which blocks the post-translational intracellular formation of hypusine, in an amount sufficient to: suppress biosynthesis of bioactive eIF-5A, suppress translational interaction of eIF-5A with viral elements of nucleic acid and/or protein structure, inhibit biosynthesis of viral proteins of Rev-dependent lentiviruses or of viruses dependent on interaction of eIF-5A with viral elements of nucleic acid and/or protein structure, inhibit replication of Rev-dependent lentiviruses or of viruses dependent on interaction of eIF-5A with viral elements of nucleic acid and/or protein structure, and induce apoptosis of virally-infected cells. This agent can be a compound of Formulae I or II and derivatives thereof as follows: ##STR1## R.sub.1, R.sub.2, R.sub.3, and R.sub.4 each individually represent a hydrogen, an alkyl, alkenyl, or alkoxy group containing 1 to about 8 carbon atoms, an aryl, aralkyl, or cycloalkyl group containing about 5 to 12 carbon atoms, or a carboalkoxy or carbamyl group containing up to 8 carbon atoms, or a peptide or peptidomimetic moiety containing 10 to about 30 carbon atoms.

  本发明涉及一种方法，该方法采用抑制细胞内蛋白eIF-5A的翻译后Hypusine形成的方法，以抑制寄生于eIF-5A的病毒感染，从而促进它们自身的复制。通过使用通称为“Hypusine抑制剂”的化合物有意地抑制感染宿主细胞中的翻译后Hypusine形成，不仅可以选择性地抑制病毒蛋白和传染性病毒颗粒的产生，而且还会在Hypusine抑制剂撤回后，在这些受病毒感染的细胞中引起细胞凋亡。分别采用这些方法，向真核细胞、组织或个体中注射一种药物，该药物阻断细胞内翻译后Hypusine的形成，其量足以抑制生物活性的eIF-5A的生物合成，抑制eIF-5A与核酸和/或蛋白质结构的病毒元素的翻译相互作用，抑制Rev依赖性lentivirus或依赖于eIF-5A与病毒核酸和/或蛋白质结构元素相互作用的病毒蛋白的生物合成，抑制Rev依赖性lentivirus或依赖于eIF-5A与病毒核酸和/或蛋白质结构元素相互作用的病毒的复制，并诱导受病毒感染的细胞凋亡。该药物可以是如下式I或II及其衍生物的化合物：##STR1##其中，R1、R2、R3和R4分别独立地表示氢、含有1至约8个碳原子的烷基、烯基或烷氧基、含有约5至12个碳原子的芳基、芳基烷基或环烷基，或含有高达8个碳原子的羧基烷氧基或氨基甲酰基，或含有10至约30个碳原子的肽或肽类似物基团。